topotecan has been researched along with ve 821 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE | 1 |
Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM | 1 |
2 other study(ies) available for topotecan and ve 821
Article | Year |
---|---|
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan | 2013 |
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan | 2014 |